Expedited biosimilar approval

Full Title:
Expedited Access to Biosimilars Act

Summary#

This bill, the "Expedited Access to Biosimilars Act," changes what clinical testing the FDA can require for biosimilar drug approval. Its main change is to say that studies do not have to include assessments of immunogenicity, pharmacodynamics, or comparative clinical efficacy unless the Health Secretary (the head of HHS) specifically requires them and explains why early in the process. The bill aims to speed up or simplify the path for biosimilar approval.

  • Main change: Clinical studies for biosimilars must include pharmacokinetic studies (how the drug moves through the body) and clinical studies showing safety, purity, and potency in appropriate uses, but they do not have to include immunogenicity, pharmacodynamics, or comparative clinical efficacy unless the Secretary orders those assessments and gives a written justification by the earliest filing date.
  • Who decides: The Health Secretary may require the omitted assessments at their discretion, but must give written notice and justification by the earliest date the applicant can file.
  • Scope: Applies to biosimilar applications submitted on or after the bill’s enactment.
  • Goal stated by the change: Expedite access to biosimilars by narrowing default clinical study requirements.

What it means for you#

  • Biosimilar manufacturers / drug developers

    • Could need fewer types of clinical tests by default, mainly pharmacokinetic studies and clinical studies focused on demonstrating safety, purity, and potency.
    • May face lower development time and complexity if the Secretary does not require extra assessments.
    • Still must provide extra assessments (immunogenicity, pharmacodynamics, or comparative efficacy) if the Secretary asks and provides a written reason early.

  • Patients and clinicians

    • More biosimilars could reach the market sooner if sponsors can do fewer clinical assessments.
    • Clinical safety or effectiveness questions that would have been addressed by immunogenicity or comparative efficacy studies might instead rely more on laboratory and pharmacokinetic data, unless the Secretary requires those clinical assessments.

  • Insurers, employers, and patients who pay for drugs

    • Faster or cheaper entry of biosimilars could increase competition and potentially lower prices; this is a possible effect, not a guaranteed outcome.

  • Food and Drug Administration (HHS)

    • Gains explicit discretion to require or not require certain clinical assessments.
    • Must provide written justification for requiring additional assessments by the earliest filing date.

Expenses#

No publicly available information.

  • The bill text does not include a fiscal note or cost estimate.
  • Reasonable inferences: reducing clinical study requirements could lower development costs for manufacturers; effects on FDA review workload and federal spending are not specified.
  • Any changes to FDA staffing, review work, or downstream health system costs are not described in the bill material.

Proponents' View#

(The following are possible arguments that follow from the bill text. They are not direct quotes from sponsors.)

  • The bill appears intended to speed up approval of biosimilars by narrowing routine clinical study requirements.
  • Supporters may argue this reduces time and cost for biosimilar development, encouraging more competition and wider patient access.
  • The bill keeps a baseline requirement for pharmacokinetic studies and clinical proof of safety, purity, and potency, while giving the Secretary discretion to require extra testing when needed.
  • Requiring a written justification early could give applicants clarity about what tests regulators will ask for.

Opponents' View#

(These are potential concerns that follow from the bill text.)

  • One concern is that removing routine requirements for immunogenicity, pharmacodynamics, and comparative efficacy could leave gaps in clinical evidence about how a biosimilar behaves in patients, especially for immune reactions.
  • It is unclear how often the Secretary would require the omitted assessments in practice; that uncertainty could affect clinician and patient confidence.
  • The bill does not include details on how the Secretary should decide when extra assessments are needed beyond the written justification timing.
  • There is no fiscal estimate, so the effects on FDA resources or on long-term health costs are uncertain.
  • If fewer clinical data are collected before approval, post-market monitoring needs could increase; the bill does not address post-approval surveillance.

What is unclear: The bill does not explain the criteria the Secretary must use to decide when to require immunogenicity, pharmacodynamics, or comparative efficacy assessments, nor does it provide cost or timing estimates.